Lawrence Leung
Academic Appointments
- Professor, Medicine - Hematology
- Member, Cancer Center
Contact Information
-
Clinical Offices
Hematology Clinic 300 Pasteur Dr A175 MC 5312 Stanford, CA 94305 Tel Work (650) 725-4036 Fax (650) 736-0974Hematology Clinic 875 Blake Wilbur Dr Clinic C Stanford, CA 94305-5820 Tel Work (650) 498-6000 Fax (650) 498-5030
Professional Snapshot
Clinical Focus
- Cancer> Hematology
- Hematology
Professional Education
| Board Certification: | Hematology, American Board of Internal Medicine (1980) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (1978) |
| Board Certification: | Medical Oncology, American Board of Internal Medicine (1981) |
| Fellowship: | New York Hospital, NY (1981) |
| Residency: | New York Hospital, NY (1978) |
Postdoctoral Advisees
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information
| Consulting: | Gilead Sciences |
Scientific Focus
Current Research Interests
Our long-term interest is to have a better understanding of the natural antithrombotic pathways and the pathophysiology of vascular thrombosis. We have focused on the biology of thrombin, the key enzyme in the clotting cascade. Using a library of thrombin mutants generated by site-directed mutagenesis, we have mapped the critical functional sites on thrombin for its interactions with its diverse substrates. We are studying a carboxypeptidase that plays a key role in the physiologic regulation of thrombin’s pro-thrombotic and pro-inflammatory properties. Using transcript profiling of human vascular endothelial cells, we have recently identified a novel endothelial cell surface protein, which may serve as a new disease marker. Our goal is to develop new antithrombotic agents and devise new diagnostic tests for vascular thrombotic disorders.
Clinical Trials
Publications
- Heparin-induced thrombosis without thrombocytopenia. J Thorac Cardiovasc Surg. 2010; (2): e6-7
- Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem. 2009; (2): 751-8
- Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol. 2008; (16): 4080-3
- Thrombin hydrolysis of human osteopontin is dependent on thrombin anion-binding exosites. J Biol Chem. 2008; (26): 17789-96
- Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Adv Exp Med Biol. 2008: 61-9
Help